| Title |
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
|
|---|---|
| Published in |
The Lancet, May 2020
|
| DOI | 10.1016/s0140-6736(20)31042-4 |
| Pubmed ID | |
| Authors |
Ivan Fan-Ngai Hung, Kwok-Cheung Lung, Eugene Yuk-Keung Tso, Raymond Liu, Tom Wai-Hin Chung, Man-Yee Chu, Yuk-Yung Ng, Jenny Lo, Jacky Chan, Anthony Raymond Tam, Hoi-Ping Shum, Veronica Chan, Alan Ka-Lun Wu, Kit-Man Sin, Wai-Shing Leung, Wai-Lam Law, David Christopher Lung, Simon Sin, Pauline Yeung, Cyril Chik-Yan Yip, Ricky Ruiqi Zhang, Agnes Yim-Fong Fung, Erica Yuen-Wing Yan, Kit-Hang Leung, Jonathan Daniel Ip, Allen Wing-Ho Chu, Wan-Mui Chan, Anthony Chin-Ki Ng, Rodney Lee, Kitty Fung, Alwin Yeung, Tak-Chiu Wu, Johnny Wai-Man Chan, Wing-Wah Yan, Wai-Ming Chan, Jasper Fuk-Woo Chan, Albert Kwok-Wai Lie, Owen Tak-Yin Tsang, Vincent Chi-Chung Cheng, Tak-Lun Que, Chak-Sing Lau, Kwok-Hung Chan, Kelvin Kai-Wang To, Kwok-Yung Yuen |
X Demographics
The data shown below were collected from the profiles of 1,298 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 179 | 14% |
| United States | 153 | 12% |
| India | 39 | 3% |
| Mexico | 39 | 3% |
| United Kingdom | 32 | 2% |
| France | 19 | 1% |
| Pakistan | 19 | 1% |
| Canada | 16 | 1% |
| Australia | 12 | <1% |
| Other | 150 | 12% |
| Unknown | 640 | 49% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1079 | 83% |
| Scientists | 103 | 8% |
| Practitioners (doctors, other healthcare professionals) | 95 | 7% |
| Science communicators (journalists, bloggers, editors) | 21 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 1,606 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1606 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 198 | 12% |
| Researcher | 185 | 12% |
| Student > Master | 145 | 9% |
| Student > Ph. D. Student | 129 | 8% |
| Other | 117 | 7% |
| Other | 327 | 20% |
| Unknown | 505 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 384 | 24% |
| Biochemistry, Genetics and Molecular Biology | 137 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 132 | 8% |
| Immunology and Microbiology | 60 | 4% |
| Agricultural and Biological Sciences | 53 | 3% |
| Other | 251 | 16% |
| Unknown | 589 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2115. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2024.
All research outputs
#4,251
of 25,801,916 outputs
Outputs from The Lancet
#187
of 43,008 outputs
Outputs of similar age
#300
of 419,041 outputs
Outputs of similar age from The Lancet
#15
of 380 outputs
Altmetric has tracked 25,801,916 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 43,008 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 68.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 419,041 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 380 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.